Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494 502. 725. Steinhubl SR, Berger PB, Mann JT, III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411 20. 726. Helton TJ, Bavry AA, Kumbhani DJ, et al. Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials. Am J Cardiovasc Drugs. 2007;7:289 97. 727. Sirois C, Poirier P, Moisan J, et al. The benefit of aspirin therapy in type 2 diabetes: what is the evidence? Int J Cardiol. 2008;129:172 9. 728. Shuldiner AR, O Connell JR, Bliden KP, et al. Association of cyto- chrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849 57. 729. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 poly- morphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373:309 17. Fihn et al Stable Ischemic Heart Disease: Full Text e451 730. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 poly- morphisms and response to clopidogrel. N Engl J Med. 2009;360: 354 62. 731. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363 75. 732. Price MJ, Angiolillo DJ, Teirstein PS, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation. 2011;124:1132 7. 733. Pare G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363:1704 14. 734. Gilard M, Arnaud B, Le GG, et al. 